Verastem to Host Analyst and Investor Day on May 2, 2018
April 23 2018 - 7:00AM
Business Wire
Verastem, Inc. (NASDAQ: VSTM), focused on developing and
commercializing drugs to improve the survival and quality of life
of cancer patients, today announced that it will host an Analyst
and Investor Day titled, “Duvelisib: Harnessing the Power of Dual
PI3K Inhibition,” on Wednesday, May 2, 2018 from 10:30 am – 1:00 pm
ET in New York City.
The agenda will include an in-depth discussion of the Company’s
lead oral oncology candidate, duvelisib, including the unmet need
of patients, where phosphoinositide-3-kinase (PI3K)-delta and
PI3K-gamma inhibitors fit into the treatment paradigm and the
opportunity for duvelisib in the growing chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular
lymphoma (FL) population and beyond.
The program will also feature key opinion leaders in the
hematologic oncology field, including:
- Jennifer Brown, MD, PhDAssociate
Professor of Medicine, Harvard Medical School Director, and
Director, CLL Center of the Division of Hematologic Malignancies,
Dana-Farber Cancer Institute
- Ian Flinn, MD, PhDDirector, Blood
Cancer Research Program at Sarah Cannon Research Institute, and
Lead Investigator of the DUO and DYNAMO Studies
- Steven Horwitz, MDMedical Oncologist,
Memorial Sloan Kettering Cancer Center and NYC Health +
Hospitals/Bellevue
- Brian Koffman, MDCM, DCFP, FCFP, DABFP,
MSEdPhysician, Medical Director of the Chronic Lymphocytic Leukemia
(CLL) Society and CLL Patient
- Lori Kunkel, MDOncology Drug
Development Expert and Biotech Advisor, Member of the Board of
Directors at Tocagen Inc., Former Chief Medical Officer,
Pharmacyclics
Kindly reach out to Marianne Lambertson at
mlambertson@verastem.com for any inquiries.
A live and archived webcast of the event will be available on
the “Events and Presentations” page in the “Investors” section of
the Company’s website at www.verastem.com. The webcast will be
archived for a period of 90 days following the conclusion of the
live event.
About Verastem, Inc.
Verastem, Inc. (Nasdaq:VSTM) is a biopharmaceutical company
focused on developing and commercializing drugs to improve the
survival and quality of life of cancer patients. Verastem is
currently developing duvelisib, a dual inhibitor of PI3K-delta and
PI3K-gamma, which has successfully met its primary endpoint in a
Phase 2 study in indolent non-Hodgkin lymphoma and a Phase 3
clinical trial in patients with chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL). Verastem has submitted a New Drug
Application (NDA) requesting the full approval of duvelisib for the
treatment of patients with relapsed or refractory CLL/SLL, and
accelerated approval for the treatment of patients with relapsed or
refractory follicular lymphoma (FL). The FDA has accepted the NDA
for filing with Priority Review and given a target action date of
October 5, 2018. In addition, Verastem is developing the focal
adhesion kinase inhibitor defactinib, which is currently being
evaluated in three separate clinical collaborations in combination
with immunotherapeutic agents for the treatment of several
different cancer types, including pancreatic cancer, ovarian
cancer, non-small cell lung cancer, and mesothelioma. Verastem’s
product candidates seek to treat cancer by modulating the local
tumor microenvironment and enhancing anti-tumor immunity.
For more information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180423005198/en/
Verastem, Inc.Marianne M. Lambertson, 781-292-4273Vice
President, Corporate CommunicationsInvestor Relations/Public
Relationsmlambertson@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024